RAD21-AS1: A Potential Drug Target Or Biomarker (G644660)

Target Name: RAD21-AS1

NCBI ID: G644660

RAD21-AS1

Other Name(s): RAD21 antisense RNA 1 | NCRNA00255 | C8orf81

RAD21-AS1: A Potential Drug Target Or Biomarker

RAD21-AS1 is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. It is a key regulator of the cell cycle and has been shown to play a role in a variety of cellular processes, including cell growth, apoptosis, and transcriptional regulation. In this article, we will explore the biology of RAD21-AS1 and its potential as a drug target or biomarker.

Overview of RAD21-AS1

RAD21-AS1 is a small non-coding RNA molecule that is expressed in a variety of tissues and cells. It is composed of 194 amino acid residues and has a calculated molecular mass of 21 kDa. RAD21-AS1 is predominantly expressed in the brain, heart, and testes, and is also expressed in other tissues and organs, including liver, muscle, and placenta. It is highly expressed in fetal tissues and has been shown to be involved in the development and maintenance of tissues and organs.

RAD21-AS1 has been shown to play a role in regulating the cell cycle. It is a negative regulator of the G1-S transition and is involved in the regulation of cell cycle progression from G1 to S. G1-S transitions are critical for the regulation of cell growth and development, and RAD21-AS1 is shown to be involved in the regulation of these transitions. It is also involved in the regulation of the G2-M transition, which is the stage of the cell cycle where the cell prepares for cell division.

In addition to its role in the cell cycle, RAD21-AS1 is also involved in a variety of other cellular processes. It has been shown to play a role in cell apoptosis, which is the process by which cells die when they have reached a certain level of dysfunction. RAD21-AS1 is shown to be involved in the regulation of apoptosis, and it is thought to play a role in the protection of cells from stress and damage.

RAD21-AS1 is also involved in transcriptional regulation. It has been shown to play a role in the regulation of gene expression, and is thought to be involved in the process of post-transcriptional modification (PTM). PTMs are a variety of processes that occur after the transcription of RNA, but before the translation of RNA into protein. RAD21-AS1 is shown to be involved in the regulation of PTMs, including splicing and translation.

Potential Therapeutic Applications

RAD21-AS1 has the potential to be a drug target or biomarker due to its involvement in the regulation of the cell cycle and various cellular processes. There are a variety of potential therapeutic applications for RAD21-AS1, including the treatment of cancer, neurodegenerative diseases , and other conditions.

One potential application for RAD21-AS1 is the treatment of cancer. RAD21-AS1 has been shown to play a role in the regulation of cell cycle progression, and is therefore thought to be involved in the development and progression of cancer. By targeting RAD21- AS1, it may be possible to inhibit the regulation of cell cycle progression and disrupt the development of cancer cells. This could be done through a variety of mechanisms, including inhibition of the activity of RAD21-AS1 itself, or through inhibition of the activity of RAD21-AS1-interacting proteins.

Another potential application for RAD21-AS1 is the treatment of neurodegenerative diseases. RAD21-AS1 has been shown to play a role in the regulation of the cell cycle and has been implicated in the development and progression of neurodegenerative diseases. By targeting RAD21-AS1, it may be possible to treat these conditions by inhibiting the regulation of cell cycle progression and disrupting the development of neurodegenerate

Protein Name: RAD21 Antisense RNA 1

The "RAD21-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD21-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets